Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
6/3/25 | GSK (GSK) | Zejula for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/3/25 | Johnson & Johnson (JNJ) | Akeega for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/3/25 | Pfizer (PFE) | Braftovi for Melanoma | Subscribers Only | Subscribers Only | Subscribers Only |
6/3/25 | Bristol (BMY) | Opdualag IV for Melanoma | Subscribers Only | Subscribers Only | Subscribers Only |
6/3/25 | Pfizer (PFE) | Mektovi for Melanoma | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/20/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/22/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/02/2025 | Subscribers Only | Subscribers Only | Regulatory - Supplemental Approval (Europe) |